Amoytop Biotech is listed on SSE STAR Market (Sci-tech innovation board, Shanghai Stock Exchange)

Amoytop Biotech is a leading biopharmaceutical company in China, specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..

After 14-year development, the long-acting interferon drug product of Amoytop Biotech, Pegberon® (pegylated interferon alfa-2b), national class-1 new drug, was approved in China in 2016. Pegberon is the first 40kD Y-shape branched PEG modified interferon alfa-2b injection in the world, with special structure in complete patent protection, has broken the monopoly of foreign products in treatment of viral hepatitis, and awarded with “2016 Top 10 China Medicinal Biotech Progress” by China Medicinal Biotechnology Association.

Recently, with the idea of “clinical cure” in chronic hepatitis B treatment filed has been gradually recognized by hepatitis specialists and clinicians, Amoytop Biotech has supported/conducted a series of research projects aiming to improve CHB clinical cure level, including CHB clinical cure projects listed in the National Major Scientific and Technological Special Projects during the “13th Five-year Plan” period, exploratory researches on the application and optimization of chronic hepatitis B clinical cure, and relevant confirmatory clinical trials. Through continuous exploration and accumulation, Amoytop Biotech is devoted to be the leader in CHB clinical cure field based on pegylated interferon alfa-2b.